BeiGene Ltd
Most Recent
Amarin’s Q2 Earnings and Robust 2019 Outlook
Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.
Do Analysts See Any Upside in BeiGene Stock?
Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”
Taking Stock of BeiGene’s Latest Performance
BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.
BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.
How Ionis’s Q2 2018 Earnings Trended
Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.
What Drove BeiGene Stock in March 2018?
BeiGene (BGNE) stock has risen 16.9%, from $143.73 on March 1, 2018, to $168 on March 29, 2018.
